Investor Presentaiton

Investor presentation Full year 2018 Slide 12 Completed PIONEER programme showed consistent statistically significant reductions in HbA1c and body weight Oral semaglutide lowered HbA1c by 1.0-1.8%- points by end of trial¹ Mean change in HbA1c (%-points) Oral semaglutide lowered body weight by ~2-5 kg by end of trial¹ Mean change in weight (kg) PIONEER trials 1 2 3 4 5 6 7 8 9 10 1 2 3 4 PIONEER trials 5 6 7 8 9 10 0.0% 0+ -1 -0.5% -1.0% -2 -3 -1.9* -2.9 * -1.2%* -2.8* -4 -3.5* -1.4%* -3.7* -4.1 -1.5%* -5 -4.2* -4.7* -4.3* -1.8%* -5.0* -6 -1.0%* -1.1%* -1.1%* -1.5% -1.3%* -1.2%* -1.5%* -2.0% 1 Hypothetical estimand, Mixed Model for Repeated Measurement (MMRM) * Statistically significant vs comparator (vs placebo in PIONEER 1; vs empagliflozin 25 mg in PIONEER 2; vs sitagliptin 100 mg in PIONEER 3; vs VictozaⓇ 1.8 mg in PIONEER 4; vs placebo in PIONEER 5; vs placebo in PIONEER 6; vs sitagliptin 100 mg in PIONEER 7; vs placebo in PIONEER 8; vs VictozaⓇ 0.9 mg and placebo in PIONEER 9; vs 0.75 mg dulaglutide in PIONEER 10) Note: Results shown are: PIONEER 1 and 5 for 26 weeks with 14 mg oral semaglutide, PIONEER 2, 4, 8, 9 and 10 for 52 weeks with 14 mg oral semaglutide; PIONEER 3 for 78 weeks with 14 mg oral semaglutide; PIONEER 7 for 52 weeks with a mixed dose; PIONEER 6 following occurrence of 137 MACE with a median follow-up time of 16 months. MACE: major adverse cardiovascular events; FDA: The US Food and Drug Administration novo nordisk

View entire presentation